Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature [PDF]
Antibiotics, 2023 Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and ...
Alessandro Mancuso +5 more
doaj +5 more sources
In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies [PDF]
Diagnostic Microbiology and Infectious DiseaseWe described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω-loop.
Amadesi S. +5 more
semanticscholar +5 more sources
Antibiotics, 2021 β-lactam–avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula.
Moonsuk Bae +12 more
doaj +2 more sources
In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates [PDF]
Antibiotics, 2023 The novel β-lactam/β-lactamase inhibitor combinations (βL-βLICs) are one of the last-line resources available against multidrug-resistant (MDR) Gram-negative bacteria.
Marta Palombo +5 more
doaj +2 more sources
Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance [PDF]
Antimicrobial Agents and Chemotherapy, 2018 We tested ceftazidime-avibactam and colistin against 24 carbapenem-resistant Enterobacteriaceae (CRE) isolates by time-kill studies. Ceftazidime-avibactam at 0.25×, 1×, and 4× the MIC was bactericidal against 8%, 21%, and 88% of the isolates, respectively.
Ryan K, Shields +4 more
openaire +3 more sources
Frontiers in Pharmacology, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Fan Fei +2 more
exaly +3 more sources
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
Antibiotics, 2021 Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
George L. Daikos +6 more
doaj +2 more sources
The β‐Lactams Strike Back: Ceftazidime‐Avibactam [PDF]
Pharmacotherapy, 2015 Gram‐negative resistance has reached a crucial point, with emergence of pathogens resistant to most or all available antibiotics. Ceftazidime‐avibactam is a newly approved agent combining ceftazidime and a novel β‐lactamase inhibitor with activity against multidrug‐resistant gram‐negative bacteria.
Evan J Zasowski, Jeffrey M Rybak
exaly +3 more sources
The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study
Infectious Diseases and Therapy, 2023 Introduction Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and ...
Alex Soriano +22 more
doaj +2 more sources
Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. [PDF]
International Journal of Antimicrobial AgentsEnterobacterales with carbapenemase-independent resistance to carbapenems are sometimes being selected during therapy and, on rare occasions, cause outbreaks.
S. Mushtaq +3 more
semanticscholar +2 more sources